Citations

Clear

16280 citation(s) found for "Yu, David".

Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19
Zhu, Wen , Zheng, Yongwei , Yu, Mei , Witman, Nathan , Zhou, Lu , Wei, Jianhui, Zhang, Yongguang , Nguyen, Christine , Wang, David , Janecke, Rae , Padmanabhan, Anand , White, Gilbert, Fields, Alexander T. , Kornblith, Lucy Z. , Aster, Richard H. , Zhu, Jieqing , Jobe, Shawn M. , Graham, Mary Beth, Wang, Demin , Wen, Renren , Topchyan, Paytsar , Nguyen, Christine , Wang, David , Janecke, Rae , Padmanabhan, Anand , Baumann Kreuziger, Lisa , Hari, Parameswaran , Gu, Tongjun , Kornblith, Lucy Z , Aster, Richard , Zhu, Jieqing , Cui, Weiguo , Jobe, Shawn , Graham, Mary Beth , Wang, Demin , Wen, Renren , Zhou, Lu , Kreuziger, Lisa Baumann , White, Gilbert C., Hari, Parameswaran , Cui, Weiguo

Mayo Clinic

Blood | November 22, 2024 | Volume: 145 | Issue: 6 | Pages: 635-647

10.1182/blood.2024025010 | PMID 39576992 Get It

Abstract Thromboembolic complication is common in severe coronavirus disease 2019 (COVID-19), leading to an investigation into the presence of prothrombotic antibodies akin to those found in heparin-induced thrombocytopenia (HIT). In a study of samples from 130 hospitalized patients, collected 3.6 days after COVID-19 diagnosis, 80% had immunoglobulin G (IgG) antibodies recognizing complexes of heparin and platelet factor 4 (PF4; PF4/H), and 41% had antibodies inducing PF4-dependent P-selectin expression in CpG oligodeoxynucleotide–treated normal platelets. Unlike HIT, both PF4/H-reactive and platelet-activating antibodies were found in patients with COVID-19 regardless of recent heparin exposure. Notably, PF4/H-reactive IgG antibodies correlated with those targeting the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein. Moreover, introducing exogenous RBD to or removing RBD-reactive IgG from COVID-19 plasma or IgG purified from COVID-19 plasma significantly reduced their ability to activate platelets. RBD-specific antibodies capable of platelet activation were cloned from peripheral blood B cells of patients with COVID-19. These antibodies possessed sequence motifs in the heavy-chain complementarity-determining region 3 (HCDR3), resembling those identified in pathogenic HIT antibodies. Furthermore, IgG+ B cells having these HCDR3 signatures were markedly expanded in patients with severe COVID-19. Importantly, platelet-activating antibodies present in patients with COVID-19 were associated with a specific elevation of platelet α-granule proteins in the plasma and showed a positive correlation with markers for inflammation and tissue damage, suggesting a functionality of these antibodies in patients. The demonstration of functional and structural similarities between certain RBD-specific antibodies in patients with COVID-19 and pathogenic antibodies typical of HIT suggests a novel mechanism by which RBD-specific antibodies might contribute to thrombosis in COVID-19.
LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
Colman, Howard , Walbert, Tobias , Lassman, Andrew B. , Kizilbash, Sani H. , Kamiya-Matsuoka, Carlos, Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren, Butowski, Nicholas , Forsyth, Peter, Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Levin, Victor A. , Kizilbash, Sani H , Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Eoli, Marica , Peereboom, David M. , Strowd, Roy E. , Pellerino, Alessia , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1301 Get It

Abstract BACKGROUND Recurrent anaplastic astrocytoma (AA), a grade 3 brain cancer, remains an unmet medical need. STELLAR was a phase III randomized, open-label trial of eflornithine (ornithine decarboxylase inhibitor) with lomustine versus lomustine alone, originally for patients with recurrent AA. However, as the WHO definition of AA evolved during trial conduct (e.g., excluding IDH wild-type disease), we determined results in both the original ITT population and by revised molecularly defined WHO 2021 diagnoses in pre-planned analyses. METHOD Key eligibility: age ≥ 18, AA (2016 WHO criteria), first recurrence ≥ 6 months after radiation and temozolomide, KPS ≥ 70, no imaging findings consistent with grade 4 glioblastoma. Stratification: IDH, age, resection extent, and geography. Patients were randomized to Arm A: eflornithine (2.8 g/m2 TID Q 2/3 weeks) with lomustine (90 mg/m2 Q 6 weeks) or Arm B: lomustine (110 mg/m2 Q 6 weeks). Primary endpoint was OS. The pre-specified hazard ratio (HR) goal was 0.667 based on projected median OS (mOS) increase to 18 months from 12 months. RESULTS 343 pts (172/171 Arms A/B) were randomized (105 sites, 8 countries). ITT analysis found no difference between arms (mOS 23.4 vs. 20.3 months, HR = 0.94). However, a pre-specified subset analysis in IDH mutant, 2021 WHO-defined grade 3 astrocytoma (n=194), showed significant improvement with eflornithine (mOS 34.9 vs. 23.5 months, HR = 0.64, log rank p = 0.016) and PFS (15.8 vs. 7.2 months, HR = 0.58, log rank p = 0.015). No difference was observed in the IDH wild-type subset. AEs were consistent with historic data. CONCLUSION There was no difference in OS between arms in the ITT analysis. However, medically meaningful and statistically significant OS and PFS benefits were observed with eflornithine in the pre-planned analysis of patients with molecularly defined 2021 WHO CNS grade 3 astrocytoma.
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Mellinghoff, Ingo K. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Gordon, Gary, Lassman, Andrew B. , Lim, Michael , Perry, James , Wen, Patrick Y. , Yung, W.K. Alfred , Berry, Nicholas , Graves, Todd, Detry, Michelle A. , Hyddmark, Emma Maria Viktoria, Johnsson, Adam, Kling, Heather M., Powell, Ashley A., Untch, Sarah, Aquilanti, Elisa , Blondin, Nicholas, Boulmay, Brian C., Fuente, Macarena de la, Lobbous, Mina , Mikkelsen, Tom , Newton, Herbert B. , Schiff, David , Sherman, Wendy, Weathers, Shiao-Pei, Friend, John, Lee, E., Mellinghoff, Ingo K , Cloughesy, Timothy F. , Alexander, Brian M. , Cavenee, Webster K. , Colman, Howard , Groot, John de , Ellingson, Benjamin M. , Khasraw, Mustafa , Sulman, Erik P. , Weller, Michael , Wen, Patrick Yung , Johnsson, Adam, McGlothlin, Anna , Powell, Ashley, Drappatz, Jan , Jordan, Justin T. , Kaley, Thomas , Owen, Scott , Peters, Katherine B. , Schiff, David, Weathers, Shiao‐Pei , Youssef, Michael , Friend, John

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1302 Get It

Abstract GBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. Paxalisib, a PI3K/mTOR inhibitor, is the 3rd arm in the trial to conclude evaluation. METHODS Paxalisib was open to patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma, with three possible signatures: NDU, RD, and All(NDU+RD). Arm enrollment occurred Dec2020 through May2022. Control patients were enrolled from study initiation (July2019) and were treated with temozolomide(NDU) or lomustine(RD). GBM AGILE investigational arms have 1 or 2 stages, with adaptive randomization in stage 1 and fixed randomization if arms continue to stage 2. Efficacy is based on OS hazard ratio(HR) of Arm/Control. Efficacy goal is final Bayesian probability ≥ 98% for HR<1.00 in combined Stages. An Arm continues to Stage 2 if Bayesian predictive power (PP) ≥ 0.8. An Arm stops accruing in Stage 1 if it reaches maximal sample size(N) or does not meet a minimum efficacy threshold (PP<0.25 for all signatures when N>50). Clinical cut-off is 12 months after accrual stops. The maximum N for paxalisib was approximately 150(Stage 1) and 50(Stage 2). RESULTS After paxalisib reached >150 patients in Stage 1, accrual stopped [Paxalisib/control N 54/75(NDU), 100/188(RD)]. Neither PP thresholds for moving to Stage 2 nor stopping for minimum efficacy were met. Following an unplanned public disclosure that the arm did not continue to stage 2, clinical cut-off for final analysis (planned May2023) was updated to public disclosure date (August2022). At final analysis mean HRs were 0.89(NDU), 1.25(RD), 1.05(All), probabilities of HR<1.00 of 0.72(NDU), 0.076(RD), 0.398(All). Model estimated median OS paxalisib/control (months) were 14.77/13.84(NDU) and 8.58/10.06(RD). CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.
Association of left atrial function with vascular brain injury: The Atherosclerosis Risk in Communities study
Wang, Wendy , Lutsey, Pamela L. , Reyes, Jorge L. , Mosley, Thomas H. , Johansen, Michelle C. , Alonso, Álvaro , Jack, Clifford R. , Solomon, Scott D. , Shah, Amil, Wasserman, Bruce A. , Shah, Amil M. , Johansen, Michelle C , Jack, Clifford R , Alonso, Alvaro , Lutsey, Pamela L , Shah, Amil , Inciardi, Riccardo M. , Gottesman, Rebecca F. , Solomon, Scott David , Chen, Lin Y.

Mayo Clinic

European Journal of Neurology | November 21, 2024 | Volume: 32 | Issue: 1 | Pages: No page available

10.1111/ene.16549 | PMID 39569699 Get It

AbstractBackground and purposeLower left atrial (LA) function is associated with higher dementia risk and may be mechanistically linked through vascular brain injury, an established correlate for higher dementia risk. Using data from the Atherosclerosis Risk in Communities study, we assessed the cross‐sectional association between LA function and brain magnetic resonance imaging (MRI) markers of vascular brain injury.MethodsWe included 1488 participants who were free of prevalent dementia, stroke, or atrial fibrillation and who underwent a two‐dimensional echocardiogram and brain MRI in 2011–2013 (mean [± standard deviation] age 76 [± 5] years, 60% female, 27% Black). LA function measures (reservoir, conduit, contractile strain) were assessed in quartiles. Brain MRI measures included cerebral microbleeds, brain infarcts, and white matter hyperintensity (WMH) volume. Logistic regression was used for dichotomous outcomes. Linear regression was used for WMH volume.ResultsOverall, 343 (23%) and 344 participants (23%) had ≥1 cerebral microbleed or brain infarct. After multivariable adjustments, the lowest LA reservoir and conduit strain quartiles (vs. highest quartile) were associated with higher odds of the presence of ≥1 cerebral microbleed (odds ratios [95% confidence intervals] 1.78 [1.42–2.22] and 1.52 [1.22–1.90]). Compared to the highest quartile, participants in the lowest LA conduit strain quartile had 1.51 (95% confidence interval 1.22–1.88) times higher odds of having ≥1 brain infarct. Lower LA contractile strain was associated with lower odds of brain infarcts. No association with WMH volume was noted.ConclusionsWe found that LA reservoir and conduit strain were associated with cerebral microbleeds and brain infarcts. Lower LA function may be linked to dementia risk via vascular brain injury. Prospective studies are needed to confirm these findings.
Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Registry Study
Martin, Robert C.G. , White, Rebekah R. , Bilimoria, Malcolm M., Kluger, Michael D. , Hammil, Chet W., Heithaus, Robert Evans , Welling, Theodore H., Chan, Carlos H.F. , Chan, Carlos H F , White, Rebekah R , Iannitti, David A. , Polanco, Patricio Marcelo , Cleary, Sean P.

Mayo Clinic

Cancers | November 21, 2024 | Volume: 16 | Issue: 23 | Pages: 3894

10.3390/cancers16233894 | PMID 39682087 Get It

Background/Objectives: Overall survival for patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) remains limited, with a median survival of 12 to 15 months. Irreversible electroporation (IRE) is a local tumor ablation method that induces cancerous cell death by disrupting cell membrane homeostasis. The DIRECT Registry study was designed to assess the effectiveness and safety of IRE when combined with standard of care (SOC) treatment for Stage 3 PDAC versus SOC alone in a real-world setting after at least 3 months of induction chemotherapy; Methods: Patients with Stage 3 PDAC treated with IRE plus SOC or SOC alone were prospectively enrolled in a multicenter registry study. Enrollment required 3 months of active multi-agent chemotherapy with no progression before enrollment. Endpoints were 30- and 90-day mortality and adverse events (AEs). Results: Eighty-seven IRE and 27 SOC subjects were enrolled in the registry. Mean ages were 64.0 ± 8.4 and 66.4 ± 9.9 years, and mean anterior/posterior tumor diameters were 2.2 ± 0.7 cm and 3.2 ± 1.3 for the IRE and SOC groups respectively (p = 0.0066). All IRE procedures were performed using an open approach. The 90-day all-cause mortality was 5/83 (6.0%) and 2/27 (7.4%) for the IRE and SOC groups, respectively. Two subjects in the IRE group died from treatment-related complications, and one patient in the SOC group died due to chemotherapy-related complications. Conclusions: Initial results from the DIRECT registry study indicate the use of IRE for curative intent tumor ablation in combination with induction chemotherapy has equivalent morbidity and mortality rates when compared to standard-of-care chemotherapy alone.
Bevacizumab: The future of chronic subdural hematoma
Verma, Yash , Abdelghaffar, Mariam , Verma, Onam , Gajjar, Aryan, Ghozy, Sherief , Kallmes, David F. , Ghozy, Sherief , Gajjar, Aryan

Mayo Clinic

Interventional Neuroradiology | November 21, 2024 | Volume: 32 | Issue: 4 | Pages: 1954-1965

10.1177/15910199241298727 | PMID 39569567 Get It

Bevacizumab (BCZ), commercially known as Avastin, is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). Initially recognized as a breakthrough in oncology, it has since gained FDA approval for various ocular conditions and more recently, for the treatment of glioblastoma multiforme (GBM). Bevacizumab's ability to inhibit excessive neovascularization suggests it may have a potential role in treating chronic subdural hematomas (cSDH). Recent studies have shown that the pathophysiology of cSDH is more complex than previously understood, with VEGF concentrations in subdural fluid significantly exceeding those in serum, contributing to the high recurrence rates. Intra-arterial administration of bevacizumab has shown promising results in recent case series against chronic subdural hematoma, and may be a viable alternative to middle meningeal artery embolization. If successful, this treatment could significantly decrease the rate of recurrence and result in lower rates of severe neurological complications such as visual loss. This literature review explores the connection between bevacizumab and cSDH, focusing on the pharmacological, safety, and delivery aspects of this approach while summarizing the current evidence supporting its use.
Bioengineered Human Arteries for the Repair of Vascular Injuries in an Extremity Injury Subset of Trial Participants
Moore, Ernest E. , Kundi, Rishi, Rajani, Ravi R. , Sokolov, Oleksandr , Niklason, Laura E. , Khondker, Zakaria, Parikh, Shamik , Investigators, CLN-PRO-V005 Investigators and the CLN-PRO-V017, Kundi, Rishi, Brenner, Megan , Lum, Ying Wei, Namias, Nicholas, Fujitani, Roy M. , Magee, Gregory A. , Batista, Philip M. , Trani, Jose, Oresanya, Lawrence , Sjoholm, Lars Ola, Calero, Aurelia, Seamon, Mark J. , Malas, Mahmoud B. , Clouse, Darrin, Naslund, Thomas C., Callcut, Rachael A. , Grandas, Oscar H., Skarupa, David , Southerland, Kevin W. , Freeman, Carl, Hurie, Justin , Goldin, Ilya, Karram, Tony, Greenberg, George, Halak, M., Skupyy, Oleh, Yurets, Serhii, Stanko, Oleksandr , Curi, Michael A. , Namias, Nicholas , Kundi, Rishi, Lum, Ying Wei , Fox, Charles J. , Rasmussen, Todd E. , Investigators, CLN-PRO-V005 Investigators and the CLN-PRO-V017, Kundi, Rishi, Morrison, Jonathan J. , Lum, Ying Wei, Shores, Jaimie T. , Namias, Nicholas, Schreiber, Martin J. , Halak, Moshe, Shaprynskyi, Vasyl V.

Mayo Clinic

JAMA Surgery | November 20, 2024 | Volume: 160 | Issue: 2 | Pages: 181

10.1001/jamasurg.2024.4893 | PMID 39565635 Get It

Importance Vascular injuries require urgent repair to minimize loss of limb and life. Standard revascularization relies on autologous vein or synthetic grafts, but alternative options are needed when adequate vein is not feasible and when clinical conditions preclude safe use of synthetic materials. Objective To evaluate the performance of the acellular tissue engineered vessel (ATEV) in the repair of extremity arterial injuries. Design, Setting, and Participants Two open-label, single-arm, nonrandomized clinical trials, including 1 prospective civilian study (CLN-PRO-V005 [V005]) and 1 retrospective observational study in a war zone (CLN-PRO-V017 [V017]), were conducted from September 2018 to January 2024 (follow-up ongoing) at 19 level 1 trauma centers in the US and Israel and 5 frontline hospitals in Ukraine. Patients had vascular injury, no autologous vein available for emergent revascularization, and risk factors for wound infection. Data include the subset of patients with extremity injuries and were analyzed from September 2023 to January 2024. Intervention The ATEV is a bioengineered vascular conduit grown from human vascular cells, available off the shelf, and implantable without immunosuppression. Main Outcomes and Measures Primary patency at day 30 was the primary outcome. Secondary outcomes included limb salvage, graft infection, and patient survival. A systematic literature review identified synthetic graft benchmarks in the treatment of arterial trauma for the same end points. Results The arterial extremity injury subset included 51 of 69 participants in V005 and 16 of 17 participants in V017. The majority were male (V005, 38 [74.5%]; V017, 16 [100%]), the mean (SD) ages were similar (V005, 33.5 [13.6] years; V017, 34.2 [9.0] years), and the mean (SD) Injury Severity Scores were similar (V005, 20.8 [10.5]; V017, 20.1 [18.9]). Penetrating injuries dominated (V005, 29 patients [56.9%]; V017, 14 patients [87.5%]). At day 30 for the V005 and V017 trials, respectively, ATEV primary patency was 84.3% (95% CI, 72.0%-91.8%) and 93.8% (95% CI, 71.7%-98.9%); secondary patency was 90.2% (95% CI, 79.0%-95.7%) and 93.8% (95% CI, 71.7%-98.9%); amputation rate was 9.8% (95% CI, 4.3%-21.0%) and 0% (95% CI, 0.0%-19.4%); ATEV infection rate was 2.0% (95% CI, 0.4%-10.3%) and 0% (95% CI, 0.0%-19.4%); and death rate was 5.9% (95% CI, 2.0%-15.9%) and 0% (95% CI, 0.0%-19.4%) (no deaths attributed to the ATEV at day 30). Day 30 synthetic graft benchmarks were as follows: secondary patency, 78.9%; amputation, 24.3%; infection, 8.4%; and death, 3.4%. Conclusions and Relevance Results of analysis in the subset of patients with vascular extremity injuries in 2 single-arm trials in civilian and real-world military settings suggest that the ATEV provides benefits in terms of patency, limb salvage, and infection resistance. Comparing ATEV outcomes with synthetic graft benchmarks demonstrated improved outcomes in the treatment of acute vascular injuries of the extremities. The analyses reported herein are limited to the subset of 67 patients with vascular extremity injuries out of 86 patients enrolled in 2 trials and excluded 19 patients with iatrogenic and torso injuries. Had these 19 patients been included in these analyses, the efficacy and safety findings could have been attenuated. Trial Registration ClinicalTrials.gov Identifiers: NCT03005418 , NCT05873959
Electrophysiologic Considerations in Adult Patients with Ebstein’s Anomaly
Hsiung, Ingrid , Fatunde, Olubadewa A. , Madhavan, Malini , Majdalany, David , Majdalany, David S , Fatunde, Olubadewa A , Srivathsan, Komandoor

Mayo Clinic

Journal of Personalized Medicine | November 20, 2024 | Volume: 14 | Issue: 11 | Pages: 1113

10.3390/jpm14111113 | PMID 39590605 Get It

Ebstein’s anomaly (EA) is a rare cyanotic form of congenital heart disease (CHD) characterized by apical displacement of the tricuspid valve, with resultant hemodynamic and electrical manifestations. The severity of symptoms is determined by the degree of apical displacement and deformity and incompetence of the tricuspid valve. As a result, patients with EA can be severely symptomatic during infancy and childhood or can be incidentally discovered in the sixth or seventh decade of life. Hallmarks of Ebstein’s anomaly include progressive cyanosis, right-sided heart failure, and tachyarrhythmias, among which tachyarrhythmias (most commonly atrial, but also ventricular) are the most common presenting symptoms in Ebstein’s anomaly patients during adulthood. This review aims to provide insight into the genetic and electrophysiological (EP) basis underlying the tachyarrhythmias encountered when managing patients with EA.
Secukinumab in bio‐experienced patients with moderate‐to‐severe hidradenitis suppurativa from a single center: an observational retrospective study
Tran, Thuy M., Tran, Thuy M., Akpala, Christeebella O. , Tran, Tung S. , Davis, Mark , Baum, Christian L. , Wetter, David A., Nguyen, Giang Huong , Akpala, Christeebella O , Tran, Tung S , Davis, Mark Denis P., Nguyen, Giang H , Tran, Thuy M., Tran, Thuy M., Davis, Mark Denis P., Alavi, Afsáneh , Wetter, David A.

Mayo Clinic

International Journal of Dermatology | November 20, 2024 | Volume: 64 | Issue: 5 | Pages: 949-951

10.1111/ijd.17583 | PMID 39564701 Get It

Response to: Correspondence on Comparative analysis of single plane and biplane angiography systems for mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis by Zhang et al
Orscelik, Atakan , Ghozy, Sherief , Brinjikji, Waleed , Kallmes, David F. , Ghozy, Sherief , Orscelik, Atakan

Mayo Clinic

Journal of NeuroInterventional Surgery | November 20, 2024 | Volume: 17 | Issue: 8 | Pages: 909-910

10.1136/jnis-2024-022756 | PMID 39567190 Get It